<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9473">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02983617</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-401-2076</org_study_id>
    <secondary_id>2016-002768-15</secondary_id>
    <secondary_id>CLLRUmbrella2</secondary_id>
    <nct_id>NCT02983617</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL)</brief_title>
  <official_title>A Prospective, Randomized, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of GS-4059 and Entospletinib With and Without Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German CLL Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine the preliminary efficacy and safety of the
      combination of tirabrutinib (formerly GS-4059) and entospletinib with and without
      obinutuzumab in adults with relapsed or refractory chronic lymphocytic leukemia (CLL).

      The primary objective is evaluation of efficacy with the secondary objective evaluation of
      safety and evaluation of additional parameters of efficacy. The treatment period is
      adaptive, with a duration of active treatment up to two years and a total follow-up on study
      of 5 years for time-dependent outcome variables. The study has a 6 patient per arm safety
      run-in to evaluate safety prior to the enrollment of subsequent participants.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 2017</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Complete Remission (CR) as Assessed by the Investigator Using the Modified International Workshop on CLL (IWCLL) 2008 criteria</measure>
    <time_frame>After the completion of 24 weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of CR with Bone Marrow Minimal Residual Disease (MRD) Negativity</measure>
    <time_frame>After the completion of 24 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of CR with Peripheral Blood MRD Negativity</measure>
    <time_frame>After the completion of 24 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>After the completion of 24 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>After the completion of 24 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Safety as Assessed by the Frequency of Treatment-Emergent Adverse Events (AE) and Treatment-Emergent Serious AEs</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Tirabrutinib + entospletinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive tirabrutinib and entospletinib for up to 104 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tirabrutinib + entospletinib + obinutuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive obinutuzumab over 21 weeks and the combination of tirabrutinib and entospletinib for up to 104 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tirabrutinib</intervention_name>
    <description>80 mg (1 x 80 mg or 4 x 20 mg) tablets administered orally once daily</description>
    <arm_group_label>Tirabrutinib + entospletinib</arm_group_label>
    <arm_group_label>Tirabrutinib + entospletinib + obinutuzumab</arm_group_label>
    <other_name>GS-4059</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entospletinib</intervention_name>
    <description>400 mg (2 x 200 mg) tablets administered orally once daily</description>
    <arm_group_label>Tirabrutinib + entospletinib</arm_group_label>
    <arm_group_label>Tirabrutinib + entospletinib + obinutuzumab</arm_group_label>
    <other_name>GS-9973</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Obinutuzumab</intervention_name>
    <description>1000 mg/40 mL single-use vials administered intravenously for a total of 8 doses over 21 weeks</description>
    <arm_group_label>Tirabrutinib + entospletinib + obinutuzumab</arm_group_label>
    <other_name>Gazyvaro®</other_name>
    <other_name>Gazyva®</other_name>
    <other_name>GA101</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Documentation of relapsed or refractory CLL

          -  Requiring treatment per modified IWCLL 2008 criteria AND radiographically measureable
             disease (defined as ≥ 1 lesion &gt; 1.5 cm in diameter as assessed by computed
             tomography (CT) or magnetic resonance imaging (MRI))

          -  Adequate hematologic function: platelet count ≥ 50 × 10^9/L, neutrophil count ≥ 1 ×
             10^9/L, hemoglobin ≥ 8 g/dL unless lower values are directly attributable to
             documented bone marrow burden of CLL

          -  Creatinine clearance (CrCl) ≥ 50 mL/min

          -  Total bilirubin ≤ 1.5× institutional upper limit of normal (ULN) unless attributed to
             Gilbert's syndrome and aspartate transaminase (AST)/alanine transaminase (ALT) ≤
             2.5×ULN

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤ 2

          -  Absence of active HIV, hepatitis B virus (HBV) infection, and hepatitis C virus (HCV)
             infection

          -  Satisfies the following criteria:

               -  For females of childbearing potential, willingness to abstain from sexual
                  intercourse or use a protocol-specified method of contraception as described in
                  the study protocol

               -  Males of reproductive potential who engage in sexual intercourse must agree to
                  use protocol-specified method(s) of contraception as described in the study
                  protocol

          -  Able to comply with study procedures and restrictions

        Key Exclusion Criteria:

          -  Known transformation of CLL (ie, Richter's transformation, prolymphocytic leukemia)

          -  Known central nervous system (CNS) involvement

          -  Prior therapy with any inhibitor of Bruton's tyrosine kinase (BTK), spleen tyrosine
             kinase (SYK), phosphatidylinositol 3-kinase (PI3K), B-cell lymphoma 2 (BCL-2), or
             obinutuzumab

          -  Any treatment for CLL other than corticosteroids for symptomatic management within 28
             days of the start of study treatment

          -  Participation on a concurrent therapeutic clinical trial unless all treatment is
             complete with only ongoing surveillance

          -  Diagnosis of or concern for progressive multifocal leukoencephalopathy

          -  History of myelodysplastic syndrome or another malignancy other than CLL, except for
             the following: any malignancy that has been in complete remission for 3 years,
             adequately treated local basal cell or squamous cell carcinoma of the skin, cervical
             carcinoma in situ, superficial bladder cancer, asymptomatic prostate cancer without
             known metastatic disease and with no requirement for therapy or requiring only
             hormonal therapy and with normal prostate-specific antigen for ≥1 year prior to start
             of study therapy

          -  Active infection requiring systemic therapy

          -  Pregnant or nursing women (a negative pregnancy test is required for all women of
             childbearing potential within 7 days before start of treatment and monthly during
             therapy)

          -  Active autoimmune disease or the need for higher than prednisone 10 mg daily unless
             for management of CLL symptoms

          -  History of stroke or intracranial hemorrhage within 12 months of randomization;
             subjects requiring therapeutic anticoagulation for any indication should be discussed
             with the German CLL Study Group (GCLLSG) cooperating physician and/or medical monitor
             prior to screening.

          -  Anticipated chronic use of strong CYP3A4/CYP2C9 inducers, moderate CYP2C9 inducers,
             or strong P-gp inducers while on study; use within 2 weeks of first dose of study
             treatment should be avoided.

          -  Requirement for proton pump inhibitor (PPI) therapy

          -  Demonstration of corrected QT (QTc) interval &gt; 450 milliseconds or requirement for
             ongoing treatment with concomitant medications that prolong the QT interval

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gilead Study Team</last_name>
    <email>GS-US-401-2076@gilead.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kreiskliniken Reutlingen GmbH Klinikum am Steinenberg</name>
      <address>
        <city>Reutlingen</city>
        <state>Baden-wuerttemberg</state>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Robert-Bosch-Krankenhaus Abteilung für Hämatologie und Onkologie</name>
      <address>
        <city>Stuttgart</city>
        <state>Baden-wuerttemberg</state>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen Klinik für Hämatologie</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-westfalen</state>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uniklinik Köln Klinik I für Innere Medizin</name>
      <address>
        <city>Köln</city>
        <state>Nordrhein-westfalen</state>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis für Hämatologie und Onkologie</name>
      <address>
        <city>Münster</city>
        <state>Nordrhein-westfalen</state>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis für Hämatologie und Onkologie</name>
      <address>
        <city>Saarbrücken</city>
        <state>Saarland</state>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum St. Marien Amberg Medizinische Klinik II</name>
      <address>
        <city>Amberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Studienzentrum Aschaffenburg</name>
      <address>
        <city>Aschaffenburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sozialstiftung Bamberg Klinikum am Bruderwald, Medizinische Klinik V</name>
      <address>
        <city>Bamberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin, Campus Benjamin Franklin Med. Klinik m. Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Evangelisches Diakoniekrankenhaus Bremen Hämatologie</name>
      <address>
        <city>Bremen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>OncoResearch Lerchenfeld GmbH</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg Med. Klinik V, Hämatologie/ Onkologie</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Westpfalz-Klinikum GmbH Med. Klinik I</name>
      <address>
        <city>Kaiserslautern</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein Klinik für Innere Medizin II - Hämatologie und Onkologie</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Lippe Lemgo Klinik für Hämatologie und Internistische Onkologie</name>
      <address>
        <city>Lemgo</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mannheimer Onkologie Praxis</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm Klinik für Innere Medizin III</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Würzburg Med. Klinik und Poliklinik II/ Zentrum für Innere Medizin</name>
      <address>
        <city>Würzburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 27, 2017</lastchanged_date>
  <firstreceived_date>December 2, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Obinutuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
